GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) and keeping the price ...

Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, ...

Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...

The recent update on the palazestrant + ribociclib combination in treating ER+/HER2- metastatic breast cancer shows encouraging results, with a high clinical benefit rate (CBR) across various patient ...

The 2024 Innovator Award will cover four years of Ramanujam and her team’s work to reduce the burdens of cancer treatments on ...

Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Nine panellists voted in favour, noting that the device’s benefits “outweigh the risks” when used as per the proposed indications to treat early-stage low-risk invasive breast cancer patients, ...